CorrectSequence Therapeutics

Gene-editing therapy hits 100% remission across 30-plus sickle cell and thalassemia patients

A base-editing therapy developed by Shanghai-based CorrectSequence Therapeutics has achieved transfusion independence or freedom from painful vaso-occlusive crises in every patient treated to date — more than 30 across four continents — according to clinical data published September 7 in…

You're all caught up

You've seen all the main stories from the past 2 days.